A liposomal RNA vaccine inducing neoantigen-specific CD4⁺ T cells augments the antitumor activity of local radiotherapy in mice

References

• Orth M, Lauber K, Niyazi M, et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys. 2014;53(1):1–29. doi:10.1007/s00411-013-0497-2.
   Google Scholar
• Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M, et al. Radiotherapy promotes tumor-specific effector cd8+t cells via dendritic cell activation. The Journal of Immunology. 2012;189(2):558–13. (Baltimore, Md.: 1950). doi:10.4049/jimmunol.1200563.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology. 2017;17(2):97–111. doi:10.1038/nri.2016.107.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li X-D, Mauceri H, Beckett M, Darga T, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–852. doi:10.1016/j.immuni.2014.10.019.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84(4):879–880. doi:10.1016/j.ijrobp.2012.06.020.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Rudqvist N-P, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–1851. doi:10.1038/s41591-018-0232-2.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu Y-X. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/JCI67313.
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Glennie MJ, Johnson PWM, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood. 2003;102(4):1449–1457. doi:10.1182/blood-2002-12-3717.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolanos E, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mabs and are dependent on Cd8 T cells and crosspriming. Cancer Res. 2016;76(20):5994–6005. doi:10.1158/0008-5472.CAN-16-0549.
   PubMed Web of Science ®Google Scholar
• Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu Y-X, et al. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016;7(28):43039–43051. doi:10.18632/oncotarget.9915.
   PubMedGoogle Scholar
• Mondini M, Nizard M, Tran T, Mauge L, Loi M, Clemenson C, Dugue D, Maroun P, Louvet E, Adam J, et al. Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer. Mol Cancer Ther. 2015;14(6):1336–1345. doi:10.1158/1535-7163.MCT-14-1015.
   PubMed Web of Science ®Google Scholar
• Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys. 2014;88(5):1188–1195. doi:10.1016/j.ijrobp.2013.12.043.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692–696. doi:10.1038/nature14426.
   PubMed Web of Science ®Google Scholar
• Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 2000;13(4):529–538. doi:10.1016/S1074-7613(00)00052-2.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. doi:10.1038/nature18300.
   PubMed Web of Science ®Google Scholar
• Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, Diken M, Löwer M, Vallazza B, Beissert T, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3ʹ UTRs identified by cellular library screening. Mol Ther: J Am Soc Gene Ther. 2019;27(4):824–836. doi:10.1016/j.ymthe.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Türeci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–4017. doi:10.1182/blood-2006-04-015024.
   PubMed Web of Science ®Google Scholar
• Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, Darzynkiewicz E, Huber C, Türeci Ö, Sahin U, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 2010;17(8):961–971. doi:10.1038/gt.2010.52.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, Huber C, Türeci Ö, Sahin U. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. The Journal of Immunology. 2008 (Baltimore, Md.: 1950);180(1):309–318. doi:10.4049/jimmunol.180.1.309.
   PubMed Web of Science ®Google Scholar
• Grunwitz C, Salomon N, Vascotto F, Selmi A, Bukur T, Diken M, Kreiter S, Türeci Ö, Sahin U. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology. 2019;8(9):e1629259. doi:10.1080/2162402X.2019.1629259.
   PubMed Web of Science ®Google Scholar
• Sahin U. et al. An RNA vaccine drives immunity in checkpoint inhibitor-experienced melanoma. Nature , 2020, accepted
   Google Scholar
• Heesen L, Jabulowsky R, Loquai C, Utikal J, Gebhardt C, Hassel J, Kaufmann R, Pinter A, Derhovanessian E, Diken M, et al. 49P A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy. Annals of Oncology. 2017;28(mdx711):030. doi:10.1093/annonc/mdx711.030.
   Google Scholar
• Jabulowsky RA, Loquai C, Derhovanessian E, Mitzel-Rink H, Utikal J, Hassel J, Kaufmann R, Pinter A, Diken M, Gold M, et al. 1238TiPA first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma. Annals of Oncology. 2018;29:viii439. doi:10.1093/annonc/mdy288.109.
   Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226. doi:10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A. 1996;93(18):9730–9735. doi:10.1073/pnas.93.18.9730.
   PubMed Web of Science ®Google Scholar
• Vormehr M, Reinhard K, Blatnik R, Josef K, Beck JD, Salomon N, Suchan M, Selmi A, Vascotto F, Zerweck J, et al. A non-functional neoepitope specific CD8 + T-cell response induced by tumor derived antigen exposure in vivo. Oncoimmunology. 2019;8(3):1553478. doi:10.1080/2162402X.2018.1553478.
   PubMed Web of Science ®Google Scholar
• Saunders CT, Wong WSW, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka. Accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinf (Oxford, England). 2012;28(14):1811–1817. doi:10.1093/bioinformatics/bts271.
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568–576. doi:10.1101/gr.129684.111.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Konrad T, Sester M, Huber C, Türeci Ö, Sahin U. Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol Immunother: CII. 2007;56(10):1577–1587. doi:10.1007/s00262-007-0302-7.
   PubMed Web of Science ®Google Scholar
• Gough MJ, Crittenden MR, Young KH. Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy. Immunother. 2015;7(8):847–849. doi:10.2217/IMT.15.58.
   PubMed Web of Science ®Google Scholar
• Diken M, Vormehr M, Grunwitz C, Kreiter S, Türeci Ö, Sahin U. Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. Methods Mol Biol. 2017;1499:223–236. doi:10.1007/978-1-4939-6481-9_14.
   Google Scholar
• Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med. 2005;11(10):1113–1117. doi:10.1038/nm1293.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031–9040. doi:10.1158/0008-5472.CAN-10-0699.
   PubMed Web of Science ®Google Scholar
• Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, Chudakov DM. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380–381. doi:10.1038/nmeth.3364.
   PubMed Web of Science ®Google Scholar
• Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV, Putintseva EV, Pogorelyy MV, Nazarov VI, Zvyagin IV, Kirgizova VI, et al. VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput Biol. 2015;11(11):e1004503. doi:10.1371/journal.pcbi.1004503.
   PubMed Web of Science ®Google Scholar
• Kim H-J, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2(2):91–98. doi:10.1158/2326-6066.CIR-13-0216.
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K.Wansley E, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–1271. doi:10.1084/jem.20052494.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. doi:10.1038/nature14292.
   PubMed Web of Science ®Google Scholar
• Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nature Reviews Cancer. 2018;18(5):313–322. doi:10.1038/nrc.2018.6.
   PubMed Web of Science ®Google Scholar
• Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466–470. doi:10.1038/nature23470.
   PubMed Web of Science ®Google Scholar
• Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280(1):249–279. doi:10.1111/imr.12573.
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–595. doi:10.1182/blood-2009-02-206870.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. The Journal of Immunology. 2005 (Baltimore, Md.: 1950);174(12):7516–7523. doi:10.4049/jimmunol.174.12.7516.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23(18):5514–5526. doi:10.1158/1078-0432.CCR-16-1673.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(17):5379–5388. doi:10.1158/1078-0432.CCR-09-0265.
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64(12):4328–4337. doi:10.1158/0008-5472.CAN-04-0073.
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen K-J, Huber SM. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol (London, England). 2014;9(1):180. doi:10.1186/1748-717X-9-180.
   PubMedGoogle Scholar
• Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nature Reviews Immunology. 2018;18(10):635–647. doi:10.1038/s41577-018-0044-0.
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637–650. doi:10.1084/jem.20091918.
   PubMed Web of Science ®Google Scholar
• Alam S, Knowlden ZAG, Sangster MY, Sant AJ. CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J Virol. 2014;88(1):314–324. doi:10.1128/JVI.02077-13.
   PubMed Web of Science ®Google Scholar
• Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, Jacobs H, Borst J. CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017;47(5):848–861.e5. doi:10.1016/j.immuni.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics. 2005;2(2):138–143. doi:10.1186/1479-7364-2-2-138.
   PubMedGoogle Scholar
• Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 2014;15(1):190. doi:10.1186/1471-2164-15-190.
   PubMedGoogle Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–5468. doi:10.1158/0008-5472.CAN-14-1258.
   PubMed Web of Science ®Google Scholar
• Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu C-G, Liu X, et al. Suppression of Type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 2017;77(4):839–850. doi:10.1158/0008-5472.CAN-15-3142.
   PubMed Web of Science ®Google Scholar
• Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70(7):2697–2706. doi:10.1158/0008-5472.CAN-09-2982.
   PubMed Web of Science ®Google Scholar
• Goding SR, Wilson KA, Antony PA. Combination of adoptive cell transfer, anti-PD-L1 and anti-LAG-3 antibodies for the treatment of recurrent tumors. Oncoimmunology. 2014;2(8):e25050. doi:10.4161/onci.25050.
   Web of Science ®Google Scholar
• Vormehr M, Türeci Ö, Sahin U. Harnessing tumor mutations for truly individualized cancer vaccines. Annu Rev Med. 2019;70(1):395–407. doi:10.1146/annurev-med-042617-101816.
   PubMedGoogle Scholar
• Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annu Rev Immunol. 2019;37(1):173–200. doi:10.1146/annurev-immunol-042617-053402.
   PubMedGoogle Scholar